Congress trades and big insider sales, sent the day they're filed. Free.
Open in Telegram
Director, Chief Executive Officer · Opus Genetics, Inc. · Common Stock
Open-market sale
$110K reported value · 1.4% of prior position
Disclosed 2 business days after execution (deadline: 2)
First recorded trade by this actor in this security
No clustered activity in the dataset
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 30 | Foundation Fighting Blindness Retinal Degeneration FundDirector, See Remarks | Open-market sale | SELL | $2.76M 556.0K sh | Oct 2, 2026 traded Sep 30, 2026 | |
| 34 | Foundation Fighting Blindness Retinal Degeneration FundDirector, See Remarks | Open-market sale | SELL | $7.39M 1.70M sh | May 20, 2026 traded May 18, 2026 | |
| 38 | Foundation Fighting Blindness Retinal Degeneration FundDirector, See Remarks | Open-market sale | SELL | $8.60M 4.00M sh | Dec 11, 2025 traded Dec 9, 2025 |
Read directly from the primary public document; every field below is as reported by the filer.
Value = shares × reported price per share
= $110,184
Magrath George filed this Form 4 reporting a open-market sale of IRD on Nov 3, 2026. It became public on Nov 5, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.